SpaceX IPO launched today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSkinbiotherap. Regulatory News (SBTX)

Share Price Information for Skinbiotherap. (SBTX)

Share Price is delayed by 15 minutes
Get Live Data
8.00    1.50 (23.08%)
Bid:
7.50
Ask:
8.50
Spread: 1.00 (13.333%)
Market Cap: £20.73m
SBTX Live PriceLast checked at - London Stock Exchange

Intraday Skinbiotherap. Share Chart

Holding(s) in Company

23 May 2017 15:21

RNS Number : 0104G
SkinBioTherapeutics PLC
23 May 2017
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

SkinBioTherapeutics

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

NO

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

YES

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

NO

An event changing the breakdown of voting rights

NO

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

SPREADEX LTD

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

15/05/2017

6. Date on which issuer notified:

23/05/2017

7. Threshold(s) that is/are crossed orreached: vi, vii

>3%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary 1 -

3,233,333

3,233,333

3,233,333

3,233,333

2.72%

GB00BF33H870

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

CFD/SPREADBET

349,778

0.30%

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

3,583,111

3.02%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

DAVID CORBEN

15. Contact telephone number:

01727 895135

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLAJMITMBBTBPR
Date   Source Headline
8th Jun 20267:30 amRNSRestoration - SkinBioTherapeutics PLC
8th Jun 20267:00 amRNSHalf-year Results (HY26) and Restated FY25 Results
28th May 20267:00 amRNSUpdate on Investigation, Interims and Auditors
12th May 202610:13 amRNSHolding(s) in Company
5th May 20262:30 pmRNSHolding(s) in Company
29th Apr 20262:30 pmRNSUpdate on the FRP Investigation
1st Apr 202610:30 amRNSHolding(s) in Company
1st Apr 20267:30 amRNSSuspension - Skinbiotherapeutics plc
1st Apr 20267:00 amRNSStatement re. Suspension
20th Mar 202611:30 amRNSUpdate On Board Investigation and Interims Date
13th Mar 20267:00 amRNSHolding(s) in Company
13th Mar 20267:00 amRNSHolding(s) in Company
9th Mar 20267:00 amRNSAppointment of the Interim CEO to the Board
2nd Mar 20267:00 amRNSAppointment of Interim CEO
20th Feb 20267:00 amRNSIndependent Investigation Appointment
16th Feb 20267:00 amRNSUpdate on Board Investigation
13th Feb 20267:00 amRNSResignation of CEO
12th Feb 202611:00 amRNSHolding(s) in Company
11th Feb 20267:00 amRNSIssue of Equity and Total Voting Rights
29th Jan 20267:00 amRNSHolding(s) in Company
22nd Jan 20269:00 amRNSTotal Voting Rights
20th Jan 20267:00 amRNSHolding(s) in Company
20th Jan 20267:00 amRNSIssue of Equity and Total Voting Rights
15th Jan 20263:21 pmRNSHolding(s) in Company
7th Jan 202611:00 amRNSHolding(s) in Company
5th Jan 20267:00 amRNSDirectorate change
2nd Jan 20267:00 amRNSHolding(s) in Company
2nd Jan 20267:00 amRNSHolding(s) in Company
29th Dec 20252:00 pmRNSResult of AGM
29th Dec 20252:00 pmRNSResult of AGM
29th Dec 20257:00 amRNSHolding(s) in Company
29th Dec 20257:00 amRNSHolding(s) in Company
18th Dec 20257:00 amRNSReconfirmation of Market Guidance and AGM Q&A
8th Dec 20252:31 pmRNSHolding(s) in Company
8th Dec 20257:00 amRNSPosting of Annual Report and AGM Notice
5th Dec 20257:00 amRNSFinal Results
26th Nov 20257:00 amRNSHolding(s) in Company
19th Nov 20257:00 amRNSHolding(s) in Company
4th Nov 20253:41 pmRNSHolding(s) in Company
14th Oct 20257:00 amRNSDirectorate Change
13th Oct 20253:31 pmRNSHolding(s) in Company
13th Oct 20253:30 pmRNSHolding(s) in Company
6th Oct 20257:00 amRNSSuperdrug first phase of store locations
1st Oct 20254:30 pmRNSHolding(s) in Company
14th Aug 20257:00 amRNSFY Trading Update
30th Jun 20257:00 amRNSCroda Commercial Launch Progressing as Expected
27th Jun 20257:00 amRNSNotice of IMC Shareholder Presentation
25th Jun 202511:28 amRNSHolding(s) in Company
20th Jun 20257:00 amRNSResult of WRAP Retail Offer
16th Jun 20252:02 pmRNSWRAP Retail Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.